about 05.27.2019 mc_101316022 copy square.jpg

Adam Gridley, MBA, Executive Chairman

Adam is currently President, CEO, and Director of Histogenics, a cell therapy and biologics company developing novel therapeutics for cartilage defects. He joined Histogenics in 2014 and completed a successful $70 million IPO, raised over $130 million, recruited a new management team, and helped lead several successful clinical and manufacturing initiatives for the Company’s Phase 3 trial of NeoCart. In addition, he completed licensing transactions with Intrexon, MEDINET (Japan), and most recently a reverse merger with Ocugen Inc. Prior to Histogenics, Adam was Senior Vice President, Technical Operations/Global Site Head at Merz Pharma, one of the world’s largest aesthetics companies. He was previously Senior Vice President of Corporate Development at BioForm Medical, where he played a key role in BioForm’s IPO, several acquisitions and product launches, and ultimately the sale of BioForm to Merz. Adam is on the Board of Directors of the Alliance for Regenerative Medicine (ARM), and the Board of Advisors for Life Science Cares, a nonprofit organization leveraging the collective impact of the Boston life sciences industry to address poverty in the Boston area. Adam holds a BS and MBA from the University of Denver.

about 05.27.2019 ReddyHeadshot.jpg

Sashank Reddy, MD, PhD, Founder, President

Sashank is Medical Director for Johns Hopkins Technology Ventures, recently appointed Assistant Professor of Plastic and Reconstructive Surgery and Biomedical Engineering at Johns Hopkins University, and a co-founder of LifeSprout. His current research efforts center on mechanisms of regeneration and homeostasis in skin and development of nanomaterials to support tissue regeneration and cell therapy. His discoveries have been published in leading journals including Nature, Cell, Cell Stem Cell and Science Translational Medicine. Sashank is also an accomplished entrepreneur and biomedical innovator. Earlier in his career he was at Third Rock Ventures where he served as a member of the founding team at Eleven Biotherapeutics (NASDAQ: SESN). In his role as Medical Director of Johns Hopkins Technology Ventures, Sashank advises faculty and University administration on enhancing the impact of discoveries through new company creation and corporate partnerships. Sashank received his undergraduate degree with University Honors from Johns Hopkins where he studied Biology and Humanistic Studies as one of the University’s Beneficial Hodson Scholars. He went on to complete MD and PhD studies at Harvard Medical School under the auspices of the NIH’s Medical Scientist Training Program.

about 06.18.2019 GOORNO eric B&W.jpg

Eric Goorno, MBA, Chief Executive Officer

Eric is the Chief Executive Officer of LifeSprout. He brings more than 25 years of operational experience in both early stage and high growth healthcare companies across multiple disease areas and medical specialties. Prior to joining LifeSprout, Eric had a long career with Boston Scientific, most recently as President of the firm’s $395 million Urology & Gynecology Division where he was responsible for establishing and driving the Division’s global strategy and sustained growth. Earlier at Boston Scientific Eric held positions as Vice President, New Market Development and Strategic Planning, Urology & Gynecology, Vice President of Operations, Microwave Divisions, and Vice President and General Manager, Symbiosis Division. After leaving Boston Scientific in 2009, he founded Pulse Veterinary Technologies, LLC where he served as Founder and CEO until the company’s successful acquisition. He then joined his next start up, BioDirection, as President and CEO before being recruited to the CEO position at LifeSprout. Earlier in his career Eric held various plant manager and operational roles at Synthes USA. Eric holds a BA from Tufts University, cum laude, in Political Science and an MBA from Harvard Business School.

about Greg-new-large[2][2].jpg

Greg Sieczkiewicz, PhD, JD, Chief IP Counsel

Greg is the founder of Picket Fence Intellectual Property and is Chief IP Counsel and Executive Partner at MPM Capital where he represents numerous portfolio companies. Prior to joining MPM, Greg was the IP strategy architect for more than a dozen venture-backed life sciences companies across the spectrum – from nucleic acid therapeutics, oral biologics and the microbiome to oncology and protein engineering. Companies Greg has advised have been the subject of major acquisitions or initial public offerings. Earlier in his career, Greg served as Vice President, IP at Flagship Ventures, and also practiced patent counseling and enforcement at national law firms Mintz Levin, Proskauer Rose and Foley Hoag. Greg is a member of the bar of the Commonwealth of Massachusetts and is admitted to practice before the U.S. Patent and Trademark Office. He is also the former President of the Boston Patent Law Association. Greg received his JD, magna cum laude, from the evening program of Suffolk University Law School and earned his PhD in Cell, Molecular and Developmental Biology from Tufts University School of Medicine and completed his post-doctoral fellowship at the National Cancer Institute. He received his AB in Biology from the College of the Holy Cross.

about 06-19-2019 MARTIN russell.jpg

Russell Martin, PhD, Founder, Director of Technology

Russ developed foundational technologies enabling the LifeSprout platform during his graduate and post-doctoral studies at Johns Hopkins. He is a co-founder of the company. Prior to this, Russ was a process engineer at Calcitec Biomaterials where he scaled production and GMP manufacturing of the company’s proprietary bone adhesive. He holds a BS in Chemistry from Stanford University and a PhD in Chemical Engineering from Johns Hopkins University.


Kevin Colbert, MS, Director of Operations

Kevin has been an operational catalyst at LifeSprout following the company’s emergence from Johns Hopkins University. He has played critical roles in the company’s pre-clinical manufacturing, validation, and fundraising efforts. Kevin holds an MS in Biomedical Engineering from Johns Hopkins University.